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Outcomes and survival in surgical treatment of the descending thoracic
aorta with acute dissection
Bozinovski J, Coselli JS. Ann Thorac Surg 2008;85:965-71.
Conclusion: Open replacement of the descending thoracic aorta or
thoracoabdominal aorta for acute type B dissection carries substantial mor-
bidity and mortality rates.
Summary: In a large majority of cases, acute type B aortic dissection is
managed medically with a favorable outcome. Certainly, aortic rupture in
the setting of acute type B dissection is an indication for emergency inter-
vention. Some centers also used continued pain or a large diameter aortic
dissection as an indication for urgent repair. In this article the authors
describe the results of open urgent or emergency repair of the descending
thoracic aorta or the thoracoabdominal aorta for acute dissection in 76
consecutive patients (72% male). The patients were acquired during a
16-year period from 1989 to 2004 and therefore represent a relatively small
component of patients treated for thoracic dissection at this center during
that time. The average age of the patients who underwent surgery for acute
type B aortic dissection was 64.1 12.2 years (range, 36-86 years), and 22%
presented with rupture. A variety of surgical adjuncts were used without a
specific protocol, including hypothermic circulatory arrest in eight patients
and left carotid bypass in 15. Spinal fluid drainage was used in only five
patients. Aortic clamp time was 38.4  17.3 minutes.
One patient died intraoperatively. The overall 30-day operative mor-
tality was 22.4%. Paraplegia occurred in 6.6%, and hemodialysis was required
in 19.7%, with about half of these patients requiring permanent hemodial-
ysis. Cardiac complications occurred in 43.4%, and 10 patients had pro-
longed respirator dependence necessitating tracheostomy. The hospital stay
was 26.0  29.7 days. Rupture was not associated with an increased risk of
operative mortality or perioperative complication.
Comment: The article highlights why it is best to avoid an operation in
acute type B dissections. Even in a center with acknowledged expertise in
thoracic aortic surgery, mortality is high and morbidity is also very high.
Because mortality and morbidity rates were the same for patients with and
without rupture, it is important to reassess indications for emergency or
urgent open thoracic aortic repair in patients with acute type B dissection.
We need better natural history data to know whether continued pain
predicts rupture or if a larger initial diameter of the dissection predicts actual
rupture. One can also see this article as providing justification for endovas-
cular repair of ruptured or severely symptomatic acute type B dissections.
Given the results here, most centers are likely to do better with endovascular
repair rather than open repair of an acute type B dissection.
Telmisartan, ramipril, or both in patients at high risk for vascular
events
ONTARGET Investigators. N Engl J Med 2008;358:1547-59.
Conclusion: The angiotensin-receptor blocker (ARB) telmisartan is
equivalent to the angiotensin-converting enzyme (ACE) inhibitor ramipril
in preventing cardiovascular events in patients with vascular disease or
diabetes.
Summary: It is well known that ACE inhibitors reduce mortality and
morbidity from cardiovascular causes in patients with vascular disease or
high-risk diabetes who do not have heart failure. ARBs have also been shown
to reduce fatal and nonfatal cardiovascular events, but have not been
previously compared with ACE inhibitors in patients with peripheral arterial
disease or high-risk diabetes. In this study, the ACE inhibitor ramipril was
compared with the ARB inhibitor telmisartan and with the combination of
the two drugs in patients with vascular disease or high-risk diabetes. This was
a noninferiority study. Patients underwent a three-way, single-arm, run-in
period and then were randomized using double-blind techniques so that
8576 patients received 10 mg of ramipril daily, 8542 received 80 mg of
telmisartan daily, and 8502 received both drugs as a combination therapy.
The primary composite outcome was myocardial infarction, stroke, hospi-
talization for heart failure, or death from cardiovascular causes.
Median follow-up was 56 months. The mean blood pressure was lower
in both the telmisartan group and the combination therapy group compared
with the ramipril group. The difference was 0.9/0.6 mg Hg in the telmis-
artan group and 2.4/1.4 mm Hg in the combination therapy group com-
pared with the ramipril group. The primary endpoint occurred in 1412
patients (16.5%) in the ramipril group and in 1423 (16.7%) in the telmisar-
tan group (relative risk, 1.05; 95% confidence interval, 0.95-1.09). The
telmisartan group had lower rates of cough than the ramipril group (1.1% vs
4.2%, P .001). The telmisartan group also had a lower rate of angioedema
than the ramipril group (0.1% vs 0.2%, P  .01) but a higher rate of
hypotensive symptoms (2.6% vs 1.7%, P .001). Syncopal rate was the same
in the two groups (0.2%). In the combination therapy group, the primary
endpoint occurred in 1386 patients (16.3%; relative risk, 0.99; 95% CI,
0.92-1.07) compared with the ramipril group. The combination therapy
group had an increased risk of hypotensive symptoms (4.8 % vs 1.7%, P 
.001), syncope (0.3% vs 0.2%, P  .03), and renal dysfunction (13.5% vs
10.2%, P  .001) than the ramipril group.
Comment: The data indicate that the ARB telmisartan is equivalent to
the ACE inhibitor ramipril in patients with vascular disease or high-risk
diabetes in reducing cardiovascular events. This is the fourth trial indicating
the ARBs are equivalent to ACE inhibitors in reducing cardiovascular events.
The clinical role of ARBs is still being defined. These drugs are more costly
than ACE inhibitors and generally have more side effects. At this point their
primary value seems to be patients who cannot tolerate ACE inhibitors
because of cough.
Long-term results of carotid stenting vs endarterectomy in high-risk
patients
Grum HS, Yadava JS, Fayad P, and the SAPPHIRE Investigators. N Engl J
Med 2008;358:1572-9.
Conclusion: There is no significant difference in long-term outcomes
in patients with severe carotid artery stenosis and increased surgical risk
treated with carotid stenting and an embolic protection device vs those
undergoing carotid endarterectomy (CEA).
Summary: The Stenting and Angioplasty with Protection in Patients at
High Risk for Endarterectomy (SAPPHIRE) trial was designed as a noninferi-
ority trial and reported 1-year results in 2004, finding carotid artery stenting
with an embolic protection device was not inferior to CEA (N Engl J Med
2004;351:1493-501). The 3-year results are reported here. Originally, 334
patients were entered in the trial. The patients were considered at increased risk
for complications for CEA and had to have had at least 50% stenosis of the
internal carotid artery to be included. Eighty percent of the patients were
asymptomatic. Prespecified major secondary endpoints at 3 years were a com-
posite of death, stroke, or myocardial infarction30 days after the procedure,
or death or ipsilateral stroke between 31 days and 1080 days (3 years).
At 3 years, data were available for 260 patients, 85.6% of the patients in
the stented group and 70.1% of patients in the CEA group. Prespecified
major secondary endpoints occurred in 41 patients in the stented group
(cumulative index, 24.6%; Kaplan-Meier estimate, 26.2%) and in 45 patients
in the endarterectomy group (cumulative index, 26.9%; Kaplan-Meier esti-
mate, 30.3%; absolute difference in cumulative incidence for the stenting
group, –2.3%; 95% CI, 11.8-7.0). There were 15 strokes in each of the two
groups, with 11 in the stenting group and nine in the CEA group being
ipsilateral to the treated artery.
Comment: This trial has a number of significant limitations, all of
which, to the authors’ credit, are indicated on the last page of the article,
before the references. These include the absence of a medical therapy group,
the fact that many of these patients in many practices would not be treated
with any intervention, the small size of the randomized cohort that prevents
meaningful subgroup analysis, incomplete follow-up at 3 years, the use of
only one type of embolic protection device, and the lack inclusion of
moderate- or low-risk patients for CEA. Finally, 10 of the 12 named authors
are financially linked to Cordis, the sponsor of the trial, or had patents linked
to the cerebral protection device used in the trial.
Significance of postoperative cross cerebellar hypoperfusion in patients
with cerebral hyperperfusion following carotid endarterectomy:
SPECT study
Ogasawara K, Kobayashi M, Suga Y, et al. Eur J Nucl Med Mol Imaging
2008;35:146-52.
Conclusion: Postoperative crossed cerebellar hypoperfusion (CCH) in
patients with cerebral hyperperfusion after carotid endarterectomy (CEA)
results in postoperative cognitive impairment even when asymptomatic.
Summary: Cerebral hyperperfusion after CEA is defined as an increase
in ipsilateral cerebral blood flow that exceeds themetabolic demands of brain
tissue. The occurrence of the cerebral hyperperfusion syndrome is charac-
terized by headache, face and eye pain, seizure, and focal symptoms. Symp-
tomatic cerebral edema or intracerebral hemorrhage occurs less often than
cerebral hyperperfusion after CEA, much of which may be asymptomatic.
There are data to suggest post-CEA cerebral hyperperfusion, as measured by
a single-photon emission computed tomography (SPECT) scanning, can be
associated with development of postoperative cognitive impairment without
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